Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
Breast Cancer Research and Treatment . 112 ( 6 ) : 971-6
DOI: 10.1038/bjc.2015.55
Article dans une revue
voir la publication